Published in J Natl Cancer Inst on August 11, 2008
Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology (2012) 10.00
Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol (2010) 5.87
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst (2009) 2.45
Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology (2014) 2.34
KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol (2012) 2.10
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int (2015) 1.92
Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med (2010) 1.86
Viral hepatocarcinogenesis. Oncogene (2010) 1.73
Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med (2012) 1.71
Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol (2009) 1.56
Hepatitis B virus mRNA-mediated miR-122 inhibition upregulates PTTG1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion. J Virol (2012) 1.36
Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev (2012) 1.30
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol (2011) 1.21
Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol (2009) 1.18
Prospective evaluation of hepatitis B 1762(T)/1764(A) mutations on hepatocellular carcinoma development in Shanghai, China. Cancer Epidemiol Biomarkers Prev (2009) 1.16
Hepatitis B virus infection and the risk of hepatocellular carcinoma. World J Gastroenterol (2011) 1.14
Molecular characteristics and stages of chronic hepatitis B virus infection. World J Gastroenterol (2009) 1.10
Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic. Dig Dis Sci (2009) 1.09
Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance. World J Hepatol (2015) 1.09
Clinical implications of hepatitis B virus mutations: recent advances. World J Gastroenterol (2014) 1.08
KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol (2016) 1.07
Associations of pri-miR-34b/c and pre-miR-196a2 polymorphisms and their multiplicative interactions with hepatitis B virus mutations with hepatocellular carcinoma risk. PLoS One (2013) 1.06
Variability in the precore and core promoter regions of HBV strains in Morocco: characterization and impact on liver disease progression. PLoS One (2012) 1.05
HLA-DP polymorphisms affect the outcomes of chronic hepatitis B virus infections, possibly through interacting with viral mutations. J Virol (2013) 1.03
Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int (2010) 1.03
Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study. Clin Exp Metastasis (2009) 1.01
Pre-S deletion and complex mutations of hepatitis B virus related to young age hepatocellular carcinoma in Qidong, China. PLoS One (2013) 1.00
Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21. Gastroenterology (2011) 1.00
ABO blood group and the risk of hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B. PLoS One (2012) 0.98
Temporal acquisition of sequential mutations in the enhancer II and basal core promoter of HBV in individuals at high risk for hepatocellular carcinoma. Carcinogenesis (2010) 0.97
HBx mutants differentially affect the activation of hypoxia-inducible factor-1α in hepatocellular carcinoma. Br J Cancer (2013) 0.97
Hepatitis C virus and hepatocarcinogenesis. Clin Mol Hepatol (2012) 0.96
Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in Qidong, China. PLoS One (2014) 0.95
Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection. Br J Cancer (2012) 0.95
Genotypes, mutations, and viral load of hepatitis B virus and the risk of hepatocellular carcinoma: HBV properties and hepatocarcinogenesis. Hepat Mon (2011) 0.95
No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations. BMC Med Genet (2012) 0.94
Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virol (2013) 0.94
Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review. World J Gastroenterol (2014) 0.93
Hepatitis B virus mutations related to liver disease progression of Korean patients. World J Gastroenterol (2014) 0.91
Viral load, genotypes, and mutants in hepatitis B virus-related hepatocellular carcinoma: special emphasis on patients with early hepatocellular carcinoma. Dig Dis Sci (2011) 0.90
Molecular epidemiology of hepatitis B virus. Korean J Intern Med (2011) 0.89
Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations. World J Gastroenterol (2013) 0.88
Hepatocellular carcinoma. Cold Spring Harb Perspect Med (2015) 0.88
Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat Mon (2012) 0.87
Hepatitis B genotypes in iran. Mater Sociomed (2014) 0.87
HBV core promoter mutations promote cellular proliferation through E2F1-mediated upregulation of S-phase kinase-associated protein 2 transcription. J Hepatol (2013) 0.87
Precore mutation of hepatitis B virus may contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. PLoS One (2012) 0.87
Altered mucosal DNA methylation in parallel with highly active Helicobacter pylori-related gastritis. Gastric Cancer (2013) 0.87
Hepatitis B virus genotypes and variants. Cold Spring Harb Perspect Med (2015) 0.86
Hepatitis B virus core promoter mutations G1613A and C1653T are significantly associated with hepatocellular carcinoma in genotype C HBV-infected patients. BMC Cancer (2011) 0.86
Hepatocellular carcinoma in Asia: Prevention strategy and planning. World J Hepatol (2015) 0.85
Number of mutations within CTL-defined epitopes of the hepatitis B Virus (HBV) core region is associated with HBV disease progression. J Med Virol (2011) 0.85
Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma. J Viral Hepat (2009) 0.85
Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001-2010. J Clin Virol (2013) 0.85
Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma. Biomark Cancer (2016) 0.85
Risk stratification of HBV infection in Asia-Pacific region. Clin Mol Hepatol (2014) 0.84
Simultaneous genotyping and quantification of hepatitis B virus for genotypes B and C by real-time PCR assay. J Clin Microbiol (2010) 0.84
Quantitative assessment of common genetic variations in HLA-DP with hepatitis B virus infection, clearance and hepatocellular carcinoma development. Sci Rep (2015) 0.84
A case-control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma. Hepatol Int (2010) 0.84
Interaction of mutant hepatitis B X protein with p53 tumor suppressor protein affects both transcription and cell survival. Mol Carcinog (2011) 0.84
Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma. J Natl Cancer Inst (2008) 0.83
Hepatitis B virus genotype, mutations, human leukocyte antigen polymorphisms and their interactions in hepatocellular carcinoma: a multi-centre case-control study. Sci Rep (2015) 0.83
Effects of hepatitis B virus mutations on its replication and liver disease severity. Open Virol J (2013) 0.83
Hepatocellular carcinoma in African Blacks: Recent progress in etiology and pathogenesis. World J Hepatol (2010) 0.82
Hepatocellular carcinoma and the risk of occupational exposure. World J Hepatol (2016) 0.82
Quantification of complex precore mutations of hepatitis B virus by SimpleProbe real time PCR and dual melting analysis. J Clin Virol (2011) 0.82
Somatic mutations, viral integration and epigenetic modification in the evolution of hepatitis B virus-induced hepatocellular carcinoma. Curr Genomics (2014) 0.82
IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. PLoS One (2013) 0.81
Hepatitis B Virus Core Promoter A1762T/G1764A (TA)/T1753A/T1768A Mutations Contribute to Hepatocarcinogenesis by Deregulating Skp2 and P53. Dig Dis Sci (2015) 0.81
Effects of genomic changes in hepatitis B virus on postoperative recurrence and survival in patients with hepatocellular carcinoma. Ann Surg Oncol (2012) 0.81
A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection. Hepatol Int (2010) 0.81
DNA markers in molecular diagnostics for hepatocellular carcinoma. Expert Rev Mol Diagn (2014) 0.80
Novel point and combo-mutations in the genome of hepatitis B virus-genotype D: characterization and impact on liver disease progression to hepatocellular carcinoma. PLoS One (2014) 0.80
Settling the "score" with liver cancer. J Hepatol (2008) 0.80
Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area: a community-based cohort study. BMC Cancer (2012) 0.80
Predictive power of hepatitis B 1762T/1764A mutations in plasma for hepatocellular carcinoma risk in Qidong, China. Carcinogenesis (2011) 0.80
The characteristic changes in hepatitis B virus x region for hepatocellular carcinoma: a comprehensive analysis based on global data. PLoS One (2015) 0.80
Binding sensitivity of adefovir to the polymerase from different genotypes of HBV: molecular modeling, docking and dynamics simulation studies. Acta Pharmacol Sin (2012) 0.80
Hepatitis B virus genetic mutations and evolution in liver diseases. World J Gastroenterol (2014) 0.80
Hepatitis B e Antigen Seroconversion Is Related with the Function of Dendritic Cells in Chronic Hepatitis B Virus Infection. Gastroenterol Res Pract (2014) 0.80
Overview of hepatitis B virus mutations and their implications in the management of infection. World J Gastroenterol (2016) 0.80
Correlations of IFN-γ-inducible protein-10 with the risk of chronic hepatitis B and the efficacy of interferon therapy in Asians. Int J Clin Exp Pathol (2015) 0.80
Development and novel therapeutics in hepatocellular carcinoma: a review. Ther Clin Risk Manag (2016) 0.79
Forfeited hepatogenesis program and increased embryonic stem cell traits in young hepatocellular carcinoma (HCC) comparing to elderly HCC. BMC Genomics (2013) 0.79
Hepatitis B virus subgenotype C2- and B2-associated mutation patterns may be responsible for liver cirrhosis and hepatocellular carcinoma, respectively. Braz J Med Biol Res (2013) 0.79
HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. BMC Gastroenterol (2015) 0.79
Precore/Core Region Mutations in Hepatitis B Virus DNA Predict Postoperative Survival in Hepatocellular Carcinoma. PLoS One (2015) 0.79
Association of Hepatitis B Virus Mutations of A1846T and C1913A/G With Acute-on-Chronic Liver Failure Development From Different Underlying Chronic Liver Diseases. Hepat Mon (2013) 0.79
High rate of core promoter and precore mutations in patients with chronic hepatitis B. Hepatol Int (2014) 0.79
Clinical utility of complex mutations in the core promoter and proximal precore regions of the hepatitis B virus genome. World J Hepatol (2015) 0.78
Quantitative evaluation of hepatitis B virus mutations and hepatocellular carcinoma risk: a meta-analysis of prospective studies. Chin J Cancer Res (2015) 0.78
Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia. World J Gastroenterol (2014) 0.78
Occult and Overt HBV Co-Infections Independently Predict Postoperative Prognosis in HCV-Associated Hepatocellular Carcinoma. PLoS One (2013) 0.78
A novel mutant 10Ala/Arg together with mutant 144Ser/Arg of hepatitis B virus X protein involved in hepatitis B virus-related hepatocarcinogenesis in HepG2 cell lines. Cancer Lett (2015) 0.78
Viral resistance in hepatitis B: prevalence and management. Curr Gastroenterol Rep (2010) 0.78
Prevalence of genotypes and subtypes of hepatitis B viruses in Bangladeshi population. Springerplus (2016) 0.78
Hepatitis B virus preS1 deletion is related to viral replication increase and disease progression. World J Gastroenterol (2015) 0.77
Hepatitis B virus infection. N Engl J Med (1997) 14.50
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 10.58
Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer (1988) 7.05
Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med (2002) 6.20
Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet (1989) 5.16
Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology (2000) 4.97
Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol (2002) 4.22
Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst (2005) 3.48
Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology (2003) 2.97
Hepatitis B genotypes and the response to interferon therapy. J Hepatol (2000) 2.97
A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology (2001) 2.80
Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med (1991) 2.75
Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol (1996) 2.68
A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med (1991) 2.68
Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology (2001) 2.62
Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol (1994) 2.41
Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology (2003) 2.38
Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology (2002) 2.34
Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A (1991) 2.05
Clinical relevance of hepatitis B viral mutations. Hepatology (2000) 2.03
Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. J Gen Virol (1992) 1.94
Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis (2006) 1.84
Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol (2002) 1.80
High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology (1999) 1.76
Naturally occurring variants of hepatitis B virus. Adv Virus Res (1999) 1.72
The precore/core promoter mutant (T1762A1764) of hepatitis B virus: clinical significance and an easy method for detection. J Gen Virol (1995) 1.64
Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene (1999) 1.63
Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol (2004) 1.58
Role of genotype and precore/basal core promoter mutations of hepatitis B virus in patients with chronic hepatitis B with acute exacerbation. Scand J Gastroenterol (2008) 1.55
Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol (2004) 1.55
Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology (1997) 1.52
Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest (1996) 1.48
Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. J Virol (1999) 1.46
Distinct modes of regulation of transcription of hepatitis B virus by the nuclear receptors HNF4alpha and COUP-TF1. J Virol (2003) 1.23
Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. Carcinogenesis (2004) 1.22
Core promoter mutations (A(1762)T and G(1764)A) and viral genotype in chronic hepatitis B and hepatocellular carcinoma in Guangxi, China. J Med Virol (2002) 1.20
Clinical and virological aspects of blood donors infected with hepatitis B virus genotypes B and C. J Clin Microbiol (2002) 1.15
Replication of the wild type and a natural hepatitis B virus nucleocapsid promoter variant is differentially regulated by nuclear hormone receptors in cell culture. J Virol (2001) 1.09
The hepatitis B virus X gene: analysis of functional domain variation and gene phylogeny using multiple sequences. J Gen Virol (1995) 1.09
Hepatitis B virus HBx gene and hepatocarcinogenesis. Intervirology (1995) 1.06
Hepatitis B virus carriers without precore mutations in hepatitis B e antigen-negative stage show more severe liver damage. Hepatology (1996) 1.05
Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. Liver Int (2005) 1.03
The molecular basis of hepatitis B e antigen (HBeAg)-negative infections. J Viral Hepat (1997) 0.96
Hepatitis B virus mutants and fulminant hepatitis B: fitness plus phenotype. Hepatology (2001) 0.87
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 10.58
Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med (2011) 6.89
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology (2006) 6.67
Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med (2002) 6.20
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A (2008) 4.06
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology (2014) 3.92
Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci U S A (2011) 3.80
Global control of hepatitis B virus infection. Lancet Infect Dis (2002) 3.74
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med (2003) 3.57
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol (2010) 3.55
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst (2005) 3.48
A novel 5-enolpyruvoylshikimate-3-phosphate (EPSP) synthase transgene for glyphosate resistance stimulates growth and fecundity in weedy rice (Oryza sativa) without herbicide. New Phytol (2013) 3.44
Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol (2011) 3.32
Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis (2012) 3.22
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med (2012) 3.20
Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst (2009) 3.19
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology (2007) 3.08
Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis (2008) 3.01
Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology (2003) 2.97
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med (2013) 2.84
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology (2002) 2.83
Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology (2008) 2.70
Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol (2005) 2.58
Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol (2013) 2.58
A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology (2008) 2.55
How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol (2007) 2.48
Control measures for severe acute respiratory syndrome (SARS) in Taiwan. Emerg Infect Dis (2003) 2.47
Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology (2008) 2.46
Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol (2013) 2.44
Clinical characteristics and prognostic factors of splenic abscess: a review of 67 cases in a single medical center of Taiwan. World J Gastroenterol (2006) 2.41
Ingested arsenic, cigarette smoking, and lung cancer risk: a follow-up study in arseniasis-endemic areas in Taiwan. JAMA (2004) 2.39
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol (2009) 2.39
HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology (2007) 2.36
High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology (2012) 2.36
Chronic hepatitis B infection in adolescents who received primary infantile vaccination. Hepatology (2012) 2.35
Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies. Am J Gastroenterol (2010) 2.32
Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology (2013) 2.29
The effects of chronic arsenic exposure from drinking water on the neurobehavioral development in adolescence. Neurotoxicology (2003) 2.29
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology (2006) 2.22
Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology (2007) 2.20
C-reactive protein concentration as a significant correlate for metabolic syndrome: a Chinese population-based study. Endocrine (2012) 2.19
Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst (2011) 2.18
P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology (2002) 2.18
Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit Care Med (2010) 2.17
Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm (2008) 2.16
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology (2003) 2.15
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol (2011) 2.12
Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology (2002) 2.12
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology (2008) 2.11